

Remarks

As directed by the Notice to Comply accompanying the Office Action dated December 29, 2009, this amendment directs the Office to enter the attached paper copy of the sequence listing into the specification. In addition, Applicants have proposed entry of the phrases "SEQ ID NO:1" and "SEQ ID NO:2" into the specification to provide sequence identifiers for the nucleotide sequences disclosed in the specification, which correspond to the sequence identifiers in the Sequence Listing currently being provided. As such, Applicants submit that the present amendment does not encompass new matter.

Applicants respectfully request entry of the proposed amendments and passage of the case for allowance.

Respectfully submitted,

/Alexander Wilson/
Alexander Wilson
Attorney for Applicants
Registration No. 45,782
Phone: 317-277-0190

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288

March 29, 2010